Search research articles
Contact Us
Filters
Showing results (211-220 of 377) with videos related to
Page
of 38
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 2, 2023
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
Carsten Denkert, Chiara Lambertini, Peter A Fasching, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2021
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Andreas Schneeweiss, Laura L Michel, Volker Möbus, et al.
Oncotarget
|
September 10, 2016
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
Silvia Darb-Esfahani, Carsten Denkert, Albrecht Stenzinger, et al.
Clinical and Translational Medicine
|
April 25, 2024
Baseline CD4<sup>+</sup> and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients
Chiara Massa, Thomas Karn, Karsten Weber, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 24, 2023
Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPE<sup>B</sup> study
José Angel García-Sáenz, Frederik Marmé, Michael Untch, et al.
Lancet (London, England)
|
May 5, 2009
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
Julia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
The Cochrane Database of Systematic Reviews
|
July 10, 2009
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data
Julia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2013
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
Gunter von Minckwitz, Volker Möbus, Andreas Schneeweiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2014
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)
Evandro de Azambuja, Marion J Procter, Dirk J van Veldhuisen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 2, 2013
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44)
Jens Huober, Peter A Fasching, Claus Hanusch, et al.
Page
of 38
Search research articles
Search
Showing results (211-220 of 377) with videos related to
Sort By:
Page
of 38
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 2, 2023
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
Carsten Denkert, Chiara Lambertini, Peter A Fasching, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2021
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Andreas Schneeweiss, Laura L Michel, Volker Möbus, et al.
Oncotarget
|
September 10, 2016
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
Silvia Darb-Esfahani, Carsten Denkert, Albrecht Stenzinger, et al.
Clinical and Translational Medicine
|
April 25, 2024
Baseline CD4<sup>+</sup> and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients
Chiara Massa, Thomas Karn, Karsten Weber, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 24, 2023
Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPE<sup>B</sup> study
José Angel García-Sáenz, Frederik Marmé, Michael Untch, et al.
Lancet (London, England)
|
May 5, 2009
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
Julia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
The Cochrane Database of Systematic Reviews
|
July 10, 2009
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data
Julia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2013
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
Gunter von Minckwitz, Volker Möbus, Andreas Schneeweiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2014
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)
Evandro de Azambuja, Marion J Procter, Dirk J van Veldhuisen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 2, 2013
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44)
Jens Huober, Peter A Fasching, Claus Hanusch, et al.
Page
of 38